Chronic Illness

Gluten

Microbiome

Mycotoxins

Nutrition

IBS And The Microbiome

Mycotoxin and Chronic illness Summit 2022

<h6>Eric D. Gordon, M.D.</h6>
Welcome. Thank you all for joining us, another edition of mycotoxins and chronic illnesses 2.0. And today, it&#8217;s my pleasure to interview and discuss all things irritable bowel and otherwise and SIBO with Dr. Mark Pimentel. Dr. Pimentel is currently director of the Medically Associated Science and Technologies Program at Cedars-Sinai, but I like to think of Dr. Pimentel as just a man who&#8217;s really helped teach us how to think about SIBO and now how to really put irritable bowel in a, I think on a much more functional, useful, forget about that, I don&#8217;t like that word functional anymore, anytime I hear functional in gastroenterology, I have problems, and Dr. Pimentel will tell us all about why I might feel that way. So, first of all, can you tell us a little bit about, actually, two minutes, about how did you wind up as a gastroenterologist doing something which, pardon me, but I love in doctors but I find too rarely in specialists, somebody who really knew that people needed to be listened to and that this was a big problem, far bigger than, you know, a little poor digestion and neurotic patients.

https://drsummits.s3.us-west-1.amazonaws.com/2022+Summits/Mycotoxins+and+Chronic+Illness+Summit+/Transcript+Files/Mycotoxins+%26+Chronic+Illness+Summit+2022-Mark+Pimentel%2C+M.D.+Transcript+File.pdf

Mark Pimentel, MD, is currently the head of the Pimentel Laboratory and executive director of the <a href="https://www.cedars-sinai.edu/research/areas/science-tech.html" data-dm-value="Medically Associated Science and Technology (MAST) Program" target="_blank" rel="noopener">Medically Associated Science and Technology (MAST) Program</a> at Cedars-Sinai. This program focuses on the development of drugs, diagnostic tests and devices related to conditions of the microbiome.
The Pimentel Lab researches irritable bowel syndrome (IBS), one of the most prevalent gastrointestinal (GI) conditions effecting about 10 percent of the population worldwide and about 10 to 15 percent of people in the U.S. In the past, there was no definitive test to diagnose IBS. For a time, IBS was thought to be a psychological disease; however, the Pimentel Lab discovered a blood test to provide a definitive diagnosis showing that IBS is an organic disease. Having a definitive diagnosis for IBS paved the way for additional research in the Pimentel Lab to treat the condition.

Mark Pimentel, MD

Eric Gordon, MD is President of Gordon Medical Research Center and clinical director of Gordon Medical Associates which specializes in complex chronic illness. In addition to being in clinical practice for over 40 years, Dr. Gordon is engaged in clinical research focused on bringing together leading international medical researchers and cutting-edge clinicians. His research is focusing on ME/CFS, Lyme disease, autoimmune diseases, and autism.

IBS And The Microbiome

Eric Gordon, MD

Mark Pimentel, MD

Summary

Content Provided By

Eric Gordon, MD

Guest Experts

Mark Pimentel, MD